Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Sana Biotechnology Inc — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $27.75, while Sana Biotechnology Inc trades at $3.2 (market cap $873.84M). The key difference: ProShares UltraShort Bloomberg Natural Gas ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| KOLD | SANA | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $5.92 |
52-Week Low | $13.58 | $2.68 |
Market Cap | — | $873.84M |
Enterprise Value | — | $848.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD trades at $28.25, up 4.01% today, with a bullish technical signal from moving averages and strong trend strength indicated by ADX. Recent news highlights natural gas market volatility driven by weather forecasts and storage reports, with the ETF positioned as a tactical trading tool amid price swings around $3/MMBtu (Seeking Alpha, 2026-06-08).
The outlook remains tied to natural gas price movements, with opportunities for short-term gains from volatility but risks from weather-dependent demand shifts and production levels. Investors face commodity price exposure and leverage risks inherent in inverse ETFs.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
